Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Differences in negative predictive value of prostate MRI based in men with suspected or known cancer.

Baghdanian AA, Kim YJ, Baghdanian AH, Nguyen HN, Shinohara K, Westphalen AC.

Radiol Bras. 2019 Sep-Oct;52(5):281-286. doi: 10.1590/0100-3984.2018.0126.

2.

Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.

Numao N, Yoshida S, Komai Y, Ishii C, Kagawa M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K.

J Urol. 2013 Aug;190(2):502-8. doi: 10.1016/j.juro.2013.02.3197. Epub 2013 Mar 7.

PMID:
23473904
3.
4.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

5.

[Diagnostic significance of multiparametric MRI combined with US-fusion guided biopsy of the prostate in patients with increased PSA levels and negative standard biopsy results to detect significant prostate cancer - Correlation with the Gleason score. Korrelation mit dem Gleason Score].

Hoffmann MA, Wieler HJ, Jakobs FM, Taymoorian K, Gerhards A, Miederer M, Schreckenberger M.

Nuklearmedizin. 2017 Aug 14;56(4):147-155. doi: 10.3413/Nukmed-0871-16-12. Epub 2017 Jul 17. German.

PMID:
28715042
6.

Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS.

Eur Urol. 2016 Mar;69(3):512-7. doi: 10.1016/j.eururo.2015.06.005. Epub 2015 Jun 22.

7.

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA.

J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.

PMID:
28373135
8.

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders GJLH, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):132-144. doi: 10.21037/tau.2017.12.29.

9.

Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T.

BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.

10.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066
11.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

12.

PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Woo S, Kim SY, Lee J, Kim SH, Cho JY.

Eur Radiol. 2016 Oct;26(10):3580-7. doi: 10.1007/s00330-016-4230-9. Epub 2016 Feb 4.

PMID:
26847042
13.

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.

Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA.

J Urol. 2013 Nov;190(5):1721-1727. doi: 10.1016/j.juro.2013.05.052. Epub 2013 May 29.

14.

Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.

Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, Hulsbergen-van de Kaa CA, Barentsz JO.

Eur Urol Focus. 2019 May;5(3):407-415. doi: 10.1016/j.euf.2017.12.008. Epub 2018 Jan 10.

PMID:
29331622
15.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.

BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.

16.

Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.

Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.

Eur Urol. 2019 Feb;75(2):310-318. doi: 10.1016/j.eururo.2018.07.031. Epub 2018 Aug 3.

PMID:
30082150
17.

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.

Ma TM, Tosoian JJ, Schaeffer EM, Landis P, Wolf S, Macura KJ, Epstein JI, Mamawala M, Carter HB.

Eur Urol. 2017 Feb;71(2):174-180. doi: 10.1016/j.eururo.2016.05.021. Epub 2016 May 25.

PMID:
27236496
18.

Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.

Bhat NR, Vetter JM, Andriole GL, Shetty AS, Ippolito JE, Kim EH.

Urology. 2019 Apr;126:152-157. doi: 10.1016/j.urology.2018.12.010. Epub 2018 Dec 20.

PMID:
30580005
19.

Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Brizmohun Appayya M, Sidhu HS, Dikaios N, Johnston EW, Simmons LA, Freeman A, Kirkham AP, Ahmed HU, Punwani S.

Br J Radiol. 2018 Feb;91(1083):20170645. doi: 10.1259/bjr.20170645. Epub 2017 Dec 15.

20.

[Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].

Zuo MZ, Zhao WL, Wei CG, Zhang CY, Wen R, Gu YF, Li MJ, Zhang YY, Wu JF, Li X, Shen JK.

Zhonghua Yi Xue Za Zhi. 2017 Dec 19;97(47):3693-3698. doi: 10.3760/cma.j.issn.0376-2491.2017.47.003. Chinese.

PMID:
29325321

Supplemental Content

Support Center